CDT Equity (CDT) Net Equity Issued and Repurchased (2022 - 2025)
CDT Equity's (CDT) quarterly Net Equity Issued and Repurchased came in at $1.7 million in Q4 2025, down 4.65% YoY from $1.8 million in Q4 2024, and down 70.99% on a QoQ basis from $6.0 million in Q3 2025.
CDT Equity (CDT) Net Equity Issued and Repurchased (2022 - 2025) Analysis & Trends
CDT Equity (CDT) has 4 years of Net Equity Issued and Repurchased data on file, last reported at $1.7 million in Q4 2025.
- Quarterly Net Equity Issued and Repurchased fell 4.65% year-over-year to $1.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $19.7 million (changed N/A YoY) and the FY2025 annual result came in at $19.7 million, up 491.92% from the prior year.
- Net Equity Issued and Repurchased retreated to $1.7 million in Q4 2025, from $6.0 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $8.1 million in Q1 2025 to a low of -$1000.0 in Q4 2023.
- A 4-year average of $3.1 million and a median of $1.8 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased tumbled 100.2% — and 2024, when it soared 182900.0%.
- Tracing CDT's Net Equity Issued and Repurchased over 4 years: stood at $511000.0 in 2022, then plunged by 100.2% to -$1000.0 in 2023, then soared by 182900.0% to $1.8 million in 2024, then decreased by 4.65% to $1.7 million in 2025.
- The last three Net Equity Issued and Repurchased figures came in at $1.7 million (Q4 2025), $6.0 million (Q3 2025), and $3.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.74 Mn |
| Dec 31, 2025 | 1.74 Mn |
| Sep 30, 2025 | 6.01 Mn |
| Sep 30, 2025 | 6.01 Mn |
| Jun 30, 2025 | 3.89 Mn |
| Jun 30, 2025 | 3.89 Mn |
| Mar 31, 2025 | 8.06 Mn |
| Mar 31, 2025 | 8.06 Mn |
| Dec 31, 2024 | 1.83 Mn |
| Dec 31, 2024 | 1.83 Mn |
| Dec 31, 2023 | -1,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Dec 31, 2022 | 511,000.00 |
| Dec 31, 2022 | 511,000.00 |